Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P22413

UPID:
ENPP1_HUMAN

ALTERNATIVE NAMES:
Membrane component chromosome 6 surface marker 1; Phosphodiesterase I/nucleotide pyrophosphatase 1; Plasma-cell membrane glycoprotein PC-1

ALTERNATIVE UPACC:
P22413; Q5T9R6; Q9NPZ3; Q9P1P6; Q9UP61; Q9Y6K3

BACKGROUND:
The protein Ectonucleotide pyrophosphatase/phosphodiesterase family member 1, known by alternative names such as Phosphodiesterase I/nucleotide pyrophosphatase 1, is integral to regulating pyrophosphate levels, thereby influencing bone mineralization and soft tissue calcification. Its enzymatic activity extends to hydrolyzing nucleoside triphosphates and modulating insulin sensitivity, highlighting its importance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Given ENPP1's involvement in a range of diseases from metabolic disorders like Type 2 diabetes mellitus to rare conditions like Cole disease, its study offers a promising avenue for therapeutic development. The enzyme's role in disease mechanisms provides a foundation for exploring targeted therapies, making it a key target in drug discovery efforts for addressing complex health issues.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.